http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
관상정맥동과의 연결이 없는 좌상대정맥의 CT 소견 : 1예 보고 case report
백상현,박재성,이혜경,홍현숙,김대호,조준희,박성진,차장규 순천향의학연구소 2004 Journal of Soonchunhyang Medical Science Vol.10 No.2
A persistent left superior vena cava (PLSVC) is the most common thoracic venous anomaly. It is a persistent remnant of a vessel that is present as a counterpart of normal right-sided superior vena cava(SVC) in early embryological development but normally disappears later. Its diagnosis can be confirmed by many noninvasive and invasive tests, or it is incidentally diagnosed at insertion into the left subclavian or jugular vein or thoracic surgery. If it is not associated with other congenital cardiac anomalies, it is usually asymptomatic and hemodynamically insignificant. We describe the chest radiograph and CT findings of bilateral SVC with drainage to left superior intercostal vein, hemiazygos, azygos vein and right SVC, and no connection of coronary sinus.
各種 疾患 患者의 血淸 및 組織에서의 Carcino-embryonic Antigen (CEA)에 關한 硏究
李賢淑,金仁仙,白承龍 고려대학교 의과대학 1982 고려대 의대 잡지 Vol.19 No.3
Carcino-embryonic antigen is a tumor-associated antigen whose testing has been considered to have a significant value in monitoring the patients with a variety of cancers. However, all the patients with malignant tumors do not reveal the elevation of serum CEA. Thus, to evaluate the relationship between serum and tissue CEA concentration, the author has studied serum CEA levels in 76 mailgnant and 89 nonmalignant diseases and demonstrated tissue CEA in 47 malignant and 13 nonmalignant diseases, using formalin-fixed, paraffin-embedded tissues and immunoperoxidase technique. The results obtained are as follows; 1. The positivity in patients with malignant diseases was 89% in pancreatic, 80% in pulmonary, 67% in hepatic, 64% in colorectal, 64% in gastric and 25% in genitourinary cancers. 2. The positivity in patients with nonmalignant diseases was 53% in gastrointestinal, 63% in hepatobiliary and pancreatic, 69% in pulmonary, 27% in genitourinary tract, 67% in cardiac and 67% in miscellaneous diseases. 3. The positivity of serum CEA in patients with gastric, colorectal and pancreatic cancers was dependent upon the extent of the diseases process. 4. The positive staining for CEA in the tissues of malingnant diseases was 81% as a whole, the staining was high in gastric, colorectal and pancreaic cancers but was low in genitourinary tract cancer, revealing correlation with the degree of staining and tumor differentiation. 5. The positive staining for CEA in the tissues of nonmalingnant diseases was 54%, but the degree of staining was weak. 6. Most of the cases, the negative staining for CEA, had serum CEA levels less than 5.0ng/ml; whereas there was no constant relationship between serum CEA levels and the degree of staining for CEA in tissues. To be brief, the findings suggested that the estimation of the serum CEA levels would be useful to aid in the diagnosis of a variety of cancers and evaluate the extent of the disease process. Also the immunohistochemical identification of CEA in tissue sections might have histopathological diagnostic implications and provide a solid basis for use of CEA in the follow-up management of cancer patients.
Helicobacter pylori와 대장균의 Shuttle Vector 개발
조명제,이우곤,이상룡,김경희,안영숙,김성희,김현주,류복덕,최여정,윤영혜,백승철,전영석,이광호 경상대학교 유전공학연구소 1997 遺傳工學硏究所報 Vol.16 No.-
In this study, a vehicle vector using cryptic plasmids was constructed for gene transfer in Helicobacter pylori. pHP51(3.9 kb) and pHP489(1.2 kb) were selected for constructing vectors from cryptic plasmid of H. pylori isolates in Korea. The HindⅢ-digestedDNA fragment(1.2kb) of pHP489 and 1.6kb DNA fragment of pHP51 were ligated with a kanamycin resistance gene(aph3'-Ⅲ) from C. jejuni to produce the recombinant plasmids pHP489K and pHP51K, respectively. Transformation frequency of pHP51K by electroporation was low. But pHP489K could be effectively transformed into various H. pylori strains. In order to design an intermdiate vehicle vector for gene transfer into H. pylori, pBlueHP489K was prepared by recloning pHP489K DNA into pBluescript and pTZ19R vector. This vector permitted the DNA fragment containing pHP489 sequence, aph3'-Ⅲ, and cloned DNA to be cut and self-ligated in the SacⅠ site after cloning. ureA and ureB gene were inserted into pBlueHP489K, resulting in pBlueHP489K/AB. The DNA fragment containing pHP489, kanamycin resistance gene(aph3'-Ⅲ), and urease structural gene was cut away from pBlueHP489K/AB and self-ligated to generate pBlueHP489K/AB. pBlueHP489K/AB made urease-negative H. pylori strains restore their urease activity. By this experiment, pBlueHP489K was confirmed to be the vehicle system for transferring H. pylori genes.
( Seung Sook Paik ),( In Kyoung Hwang ),( Myung Jae Park ),( Seung Hyeun Lee ) 대한결핵 및 호흡기학회 2018 Tuberculosis and Respiratory Diseases Vol.81 No.2
Background: Although targeted therapy and immuno-oncology have shifted the treatment paradigm for lung cancer, platinum-based combination is still the standard of care for advanced non-small cell lung cancer (NSCLC). Pemetrexed continuation maintenance therapy has been approved and increasingly used for patients with nonsquamous NSCLC. However, the efficacy of this strategy has not been proven in patients without driving mutations. The objective of this study was to compare the clinical benefit of pemetrexed continuation maintenance to conventional platinum-based doublet in epidermal growth factor receptor (EGFR)-negative lung adenocarcinoma. Methods: A total of 114 patients with EGFR-negative lung adenocarcinoma who were treated with platinum doublet were retrospectively enrolled. We compared the survival rates between patients received pemetrexed maintenance after four-cycled pemetrexed/cisplatin and those received at least four-cycled platinum doublet without maintenance chemotherapy as a first-line treatment. Results: Forty-one patients received pemetrexed maintenance and 73 received conventional platinum doublet. Median progression-free survival (PFS), which was defined as the time from the day of response evaluation after four cycles of chemotherapy to disease progression or death, was significantly higher in the pemetrexed maintenance group compared to conventional group (5.8 months vs. 2.2 months, p<0.001). Median overall survival showed an increasing trend in the pemetrexed maintenance group (22.3 months vs. 16.1 months, p=0.098). Multivariate analyses showed that pemetrexed maintenance chemotherapy was associated with better PFS (hazard ratio, 0.73; 95% confidence interval, 0.15-0.87). Conclusion: Compared to conventional platinum-based chemotherapy, premetrexed continuation maintenance treatment is associated with better clinical outcome for the patients with EGFR wild-type lung adenocarcinoma.
Paik, Seung Sook,Hwang, In Kyoung,Park, Myung Jae,Lee, Seung Hyeun The Korean Academy of Tuberculosis and Respiratory 2018 Tuberculosis and Respiratory Diseases Vol.81 No.2
Background: Although targeted therapy and immuno-oncology have shifted the treatment paradigm for lung cancer, platinum-based combination is still the standard of care for advanced non-small cell lung cancer (NSCLC). Pemetrexed continuation maintenance therapy has been approved and increasingly used for patients with nonsquamous NSCLC. However, the efficacy of this strategy has not been proven in patients without driving mutations. The objective of this study was to compare the clinical benefit of pemetrexed continuation maintenance to conventional platinum-based doublet in epidermal growth factor receptor (EGFR)-negative lung adenocarcinoma. Methods: A total of 114 patients with EGFR-negative lung adenocarcinoma who were treated with platinum doublet were retrospectively enrolled. We compared the survival rates between patients received pemetrexed maintenance after four-cycled pemetrexed/cisplatin and those received at least four-cycled platinum doublet without maintenance chemotherapy as a first-line treatment. Results: Forty-one patients received pemetrexed maintenance and 73 received conventional platinum doublet. Median progression-free survival (PFS), which was defined as the time from the day of response evaluation after four cycles of chemotherapy to disease progression or death, was significantly higher in the pemetrexed maintenance group compared to conventional group (5.8 months vs. 2.2 months, p<0.001). Median overall survival showed an increasing trend in the pemetrexed maintenance group (22.3 months vs. 16.1 months, p=0.098). Multivariate analyses showed that pemetrexed maintenance chemotherapy was associated with better PFS (hazard ratio, 0.73; 95% confidence interval, 0.15-0.87). Conclusion: Compared to conventional platinum-based chemotherapy, premetrexed continuation maintenance treatment is associated with better clinical outcome for the patients with EGFR wild-type lung adenocarcinoma.
Synthesis and Evaluation of Succinic Acid Derivatives as Prolyl Endopeptidase Inhibitors
Seung-Bin Yoon,Jae-Sung Yang,Kyung-Ho Lee,Hyeon-Gyu Han,Ah-Reum Han,Young-Sook Paik 한국응용생명화학회 2011 Applied Biological Chemistry (Appl Biol Chem) Vol.54 No.5
Many synthetic peptide-based prolyl endopeptidase (PEP) inhibitors are depended on the acyl-Lprolyl-pyrrolidine structure. The pyrrolidine ring at P1 and a large variety of lipophilic acyl groups at P3 have been reported to be important for potent PEP inhibitory activity. Upon exploration of a new lead compound for PEP inhibition, succinic acid was introduced at the P2 position to replace the L-proline in acyl-L-prolyl-pyrrolidine. A series of amido-succinylpyrrolidine compounds (1-9) were synthesized, and their PEP inhibitory activities were evaluated. Of these, compound 9 showed the most potent PEP inhibitory activity with IC50 of 6.4±0.6 nM. Many synthetic peptide-based prolyl endopeptidase (PEP) inhibitors are depended on the acyl-Lprolyl-pyrrolidine structure. The pyrrolidine ring at P1 and a large variety of lipophilic acyl groups at P3 have been reported to be important for potent PEP inhibitory activity. Upon exploration of a new lead compound for PEP inhibition, succinic acid was introduced at the P2 position to replace the L-proline in acyl-L-prolyl-pyrrolidine. A series of amido-succinylpyrrolidine compounds (1-9) were synthesized, and their PEP inhibitory activities were evaluated. Of these, compound 9 showed the most potent PEP inhibitory activity with IC50 of 6.4±0.6 nM.
Synthesis and Evaluation of Succinic Acid Derivatives as Prolyl Endopeptidase Inhibitors
( Seung Bin Yoon ),( Jae Sung Yang ),( Kyung Ho Lee ),( Hyeon Gyu Han ),( Ah Reum Han ),( Young Sook Paik ) 한국응용생명화학회 2011 Applied Biological Chemistry (Appl Biol Chem) Vol.54 No.5
Many synthetic peptide-based prolyl endopeptidase (PEP) inhibitors are depended on the acyl-Lprolyl-pyrrolidine structure. The pyrrolidine ring at P1 and a large variety of lipophilic acyl groups at P3 have been reported to be important for potent PEP inhibitory activity. Upon exploration of a new lead compound for PEP inhibition, succinic acid was introduced at the P2 position to replace the L-proline in acyl-L-prolyl-pyrrolidine. A series of amido-succinylpyrrolidine compounds (1-9) were synthesized, and their PEP inhibitory activities were evaluated. Of these, compound 9 showed the most potent PEP inhibitory activity with IC50 of 6.4±0.6 nM.